Literature DB >> 233633

Thyrotropin displacement activity of serum immunoglobulins from patients with Graves' disease.

J O'Donnell, K Trokoudes, J Silverberg, V Row, R Volpé.   

Abstract

A radioreceptor assay for human thyroid stimulators has been employed in various groups of patients. The ability of Ig to displace the labeled TSH from the receptors is referred to as "TSH displacement activity (TDA)." In active Graves' disease, TDA was above normal in 76% of the cases, and in the remaining patients, it was above the 76th percentile, suggesting that thyroid-stimulating Ig (TSIg) may have been present in all cases, but not always demonstrable by this method. Significant TDA was not found in normal persons or in toxic or nontoxic nodular goiters. It was also negative in some patients with "euthyroid ophthalmic Graves' disease." In patients with Graves' disease controlled with antithyroid drugs, positive TDA accurately predicted the recurrence of hyperthyroidism in eight of nine cases from whom the drugs were withdrawn. Thus, TSIg appears to be a prerequisite of the hyperthyroidism of Graves' disease. Moreover, the remission of hyperthyroidism was due to the disappearance of TSIg (immunological remission) in most cases in this small series. Serum TDA may provide a means of detecting immunological remission. The exophthalmos of Graves' disease does not require thyroid-stimulating Ig.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 233633     DOI: 10.1210/jcem-46-5-770

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

1.  Clinical applications of assays for thyrotropin-receptor antibodies in Graves' disease.

Authors:  J Ginsberg; C von Westarp
Journal:  CMAJ       Date:  1986-05-15       Impact factor: 8.262

2.  Changes in thyrotropin binding inhibiting immunoglobulins (TBII) in sera of patients with Graves' disease at the time of relapse or exacerbation.

Authors:  H Uchimura; N Akimoto; T Mitsuhashi; K Kubota; N Kuzuya; Y Imai; H Ikeda; F Matsuzaki; L F Kumagai
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

3.  Antibodies to the thyroid gland and to the thyrotrophin receptor in African and Indian thyrotoxic patients.

Authors:  R K Desai; I Jialal; M A Omar; M C Rajput; S M Joubert
Journal:  Postgrad Med J       Date:  1986-09       Impact factor: 2.401

4.  Interference of thyroglobulin in TSab detection by radio-receptor assay.

Authors:  G F Fenzi; L Bartalena; E Macchia; F Monzani; M Checchi
Journal:  J Endocrinol Invest       Date:  1979 Apr-Jun       Impact factor: 4.256

5.  Absence of allotypic variation in the autoantigen for thyroid stimulating autoantibodies.

Authors:  A Knight; D D Adams
Journal:  Clin Exp Immunol       Date:  1983-05       Impact factor: 4.330

Review 6.  Polyglandular autoimmune syndrome: current concepts.

Authors:  J Meyerson; E E Lechuga-Gomez; P E Bigazzi; P G Walfish
Journal:  CMAJ       Date:  1988-04-01       Impact factor: 8.262

7.  [Determination of TSH receptor antibodies--clinical value].

Authors:  E Schifferdecker; F Schulz; K Schöffling
Journal:  Klin Wochenschr       Date:  1986-01-02

8.  TSH-displacing activity versus TSH-binding inhibiting activity of immunoglobulins from patients with Graves' disease.

Authors:  E Macchia; G F Fenzi; F Monzani; L Bartalena; F Lippi; V Aloisio; C Cupini; L Baschieri; A Pinchera
Journal:  J Endocrinol Invest       Date:  1983-10       Impact factor: 4.256

9.  The production of thyroid-stimulating immunoglobulin (TSI) by lymphocytes from patients with Graves' disease cultured with human thyroid subcellular fractions.

Authors:  A Sugenoya; K Trokoudes; V V Row; R Volpé
Journal:  J Endocrinol Invest       Date:  1978-07       Impact factor: 4.256

10.  Antineutrophil autoantibodies in Graves' disease. Implications of thyrotropin binding to neutrophils.

Authors:  S A Weitzman; T P Stossel; D C Harmon; G Daniels; F Maloof; E C Ridgway
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.